Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer
Status:
Recruiting
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, double blind, prospective, placebo controlled, randomized phase III
clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined
with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative) early breast cancer
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University